Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Overview

After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will change compared to placebo in patients with chronic angina and peripheral arterial disease.

Study Endpoints: Primary Endpoint: • The primary endpoint of this study is the change in the kinetics of tissue hemoglobin oxygen desaturation (expressed as time constants) following the onset of exercise. Secondary endpoints of this study include percent and absolute change in: * Peak oxygen consumption * Pulmonary oxygen uptake on-kinetics * Steady state level of tissue hemoglobin desaturation during exercise * Recovery kinetics of tissue oxygen saturation following exercise Adverse events will be collected. Exploratory Endpoints * Peak Walking Time (PWT) * Claudication Onset Time (COT) * Time to Onset of Angina (TOA) Study Design: Investigator-initiated, prospective, randomized, double-blind, placebo-controlled study. Inclusion Criteria: 1. Males age \> 40 years. 2. Subjects must have chronic stable angina, meeting the labeled indications for ranolazine: • Ranolazine is indicated for the treatment of chronic angina. Ranolazine should be reserved for subjects who have not achieved an adequate response with other anti-anginal drugs. 3. Subjects must have a resting ankle brachial index (ABI) of \< 0.90 with a post-exercise decrement of ≥ 10% in at least one leg, OR a resting ABI of ≥0.90 to ≤ 1.00 with a post-exercise decrement of ≥ 20% in at least one leg 4. The subject has provided written informed consent to participate, understands the requirements of the study, and agrees to return for the required assessments Exclusion Criteria: 1. Non-atherosclerotic diseases of the peripheral circulation by clinical history 2. Unable to complete the first stage of the modified, extended Astrand treadmill protocol 3. Clinically significant ECG abnormalities or changes with exercise on the screening ECG 4. Evidence of critical limb ischemia (CLI) 5. Hepatic impairment (Child-Pugh Classes A \[mild\], B \[moderate\], or C \[severe\]) 6. End stage renal disease requiring dialysis 7. Hemoglobin \< 12 mg/dL. 8. Platelet count \< 90,000/mL. 9. Planned surgical/endovascular intervention for coronary artery disease (CAD) or peripheral arterial disease (PAD) in the next 3 months 10. Maximal exercise is limited by symptoms other than claudication or angina 11. Significant mental illness or drug abuse within 30 days of enrollment that in the opinion of the Investigator could impact the subject's ability to successfully complete the trial 12. Known allergy to ranolazine 13. Pre-existing QTc prolongation on a resting electrocardiogram (ECG) at Screening due to the risk of worsening of this condition with the use of ranolazine 14. Treatment with QT prolonging drugs such as Class IA (e.g. quinidine) and Class III (e.g. sotalol, dofetilide), antiarrhythmics, amiodarone, and antipsychotics (e.g. thioridazine, ziprasidone) 15. Treatment with potent or moderately potent CYP3A inhibitors including ketoconazole and other azole antifungals, diltiazem, verapamil, macrolide antibiotics, cyclosporine, rifampin or structurally related rifabutin and rifapentin, phenobarbital, phenytoin, carbamazepine, St. John's Wort, or human immunodeficiency virus (HIV) protease inhibitors 16. The subject has previously received ranolazine within the 6-months prior to enrollment 17. The subject has received an investigational drug within 90 days prior to enrollment 18. Type 1 or type 2 diabetes mellitus 19. Congestive Heart Failure, ≥ New York Heart Association (NYHA) Class III 20. History of oxygen dependent Chronic Obstructive Pulmonary Disease (COPD) 21. Body Mass Index (BMI) \>35

Conditions

Interventions

Eligibility

Locations (3)

Outcomes